Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients by Arthur E. Frankel,

Slides:

Advertisements

Similar presentations

Atypical Fractures of the Femur: Evaluation and Treatment by Travis Blood, R.J. Feller, Eric Cohen, Christopher T. Born, and Roman Hayda JBJS Reviews Volume.

Advertisements

The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz,

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic.

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 + T-cell killing by Patrizia Leone, Simona.

How I treat extramedullary myeloma

Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses by Alain H. Rook, Gary S. Wood, Elisa K. Yoo,

by Manuella L. Gomes Ochtrop, Sigune Goldacker, Annette M

by Rahul Matnani, and Karthik A. Ganapathi

Immunologic effects of F16-IL2 therapy.

Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism Gerald A. Colvin, David Berz, Muthalagu.

Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

by Christopher Dittus, and Dana Semmel

Bone Marrow Mesenchymal Stem Cell (BM-MSC) Release Microvesicles/Exosomes That Incorporate Into Hematopoietic Cells From MDS Patients and May Modify Their.

by Udomsak Bunworasate, Hilal Arnouk, Hans Minderman, Kieran L

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,

Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production by Yeon-Sook Choi, Hyun-Jung.

by Thomas S. Uldrick, and Richard F. Little

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

How I treat elderly patients with myeloma

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells by Lucie Heinzerling,

Radiofrequency ablation of lymphoma

Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection by Koen Van Besien, Sonali Smith,

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow.

Resolution of osteosclerosis after alloHCT in systemic mastocytosis

by Eli L. Diamond, Omar Abdel-Wahab, Benjamin H

Volume 19, Issue 3, Pages (March 2011)

Expression of the oncofetal ED-B–containing fibronectin isoform in hematologic tumors enables ED-B–targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma.

Volume 3, Issue 4, Pages (July 2017)

Hyaluronate-Enhanced Hematopoiesis: Two Different Receptors Trigger the Release of Interleukin-1β and Interleukin-6 From Bone Marrow Macrophages by Sophia.

T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate by E.L.

Lymphoma spread? Target CD47-SIRPα!

Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report by Richard L.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Treatment of 7 patients with relapsed/refractory NK/T-cell lymphomas treated with pembrolizumab. Treatment of 7 patients with relapsed/refractory NK/T-cell.

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation Mohamed A. Kharfan-Dabaja,

Volume 18, Issue 4, Pages (April 2010)

Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.

by Geling Li, Emily Waite, and Julie Wolfson

Volume 23, Issue 1, Pages (January 2015)

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH by Alexandra Kolenová, Raphaela Schwentner,

Hematopoietic potential of HEP from patient-specific iPSC may be reduced. Hematopoietic potential of HEP from patient-specific iPSC may be reduced. (A)

Figure 2 Assessment of systemic disease activityTc99 scintigraphy (A) and fluorodeoxyglucose PET imaging (B, C) at disease onset 2 years before acute deterioration.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

A case of lenalidomide-dependent myelodysplastic syndrome

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase by Yok-Lam Kwong, Thomas S. Y.

Targeting CD47 in Sézary syndrome with SIRPαFc

Resistance mechanism for ibrutinib in marginal zone lymphoma

IL-17A mediates cutaneous GVHD

by Naveen Pemmaraju, Hagop M. Kantarjian, Joseph David Khoury, Susan M

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

Representative staining of bone marrow aspirates collected from a patient at baseline and after 1 cycle of treatment with 45 mg/m2 selinexor + 20 mg dexamethasone,

Pure red cell aplasia by Robert T. Means Blood

Immunologic and pharmacokinetic studies.

Suggested algorithm for bone marrow biopsy and skeletal imaging in patients with monoclonal gammopathy of undetermined significance. #Mayo Clinic Risk.

Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing BALB/c mice following VP-16 pretreatment. Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing.

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI by Naranie Shanmuganathan, Susan.

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Is Skull-Base to Proximal Thigh PET/CT Enough

Presentation transcript:

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients by Arthur E. Frankel, Jung H. Woo, Chul Ahn, Naveen Pemmaraju, Bruno C. Medeiros, Hetty E. Carraway, Olga Frankfurt, Stephen J. Forman, Xuezhong A. Yang, Marina Konopleva, Francine Garnache-Ottou, Fanny Angelot-Delettre, Christopher Brooks, Michael Szarek, and Eric Rowinsky Blood Volume 124(3):385-392 July 17, 2014 ©2014 by American Society of Hematology

SL-401 concentration-time curve for patient 3 on day 1. SL-401 concentration-time curve for patient 3 on day 1. Drug concentrations assayed by a previously described bioassay.22 The Cmax and t1/2 values were 22 ng/mL and 40 minutes, respectively. Arthur E. Frankel et al. Blood 2014;124:385-392 ©2014 by American Society of Hematology

Photographs of skin, PET/CT scan, and bone marrow biopsy, pre– and post–SL-401. Photographs of skin, PET/CT scan, and bone marrow biopsy, pre– and post–SL-401. (A) Involved skin of patient 7 photographed before treatment and 4 months after treatment. (B) PET/CT images for patient 6 scanned before treatment and 1 month after treatment, demonstrating enlarged and PET-avid left inguinal node (1.2 × 1.6 cm; standardized uptake value Max 3.5) and right inguinal node (0.7 × 1 cm; standardized uptake value 2.3) before treatment. These inguinal nodes regressed and were no longer PET-avid at 1 month after treatment. (C) Immunostaining for CD123 on a bone marrow aspirated from patient 1 before treatment and at 1 month after treatment. Pretreatment showed 10% positive cells and after therapy showed <1% to 2% positive cells. Magnification pretreatment microphotograph is ×20; magnification post-treatment microphotograph is ×40. Arthur E. Frankel et al. Blood 2014;124:385-392 ©2014 by American Society of Hematology